The antiphospholipid (Hughes) syndrome (APS) is recognized as an autoimmune condition characterized by a tendency to thrombosis and, in pregnancy, to recurrent pregnancy loss. The impact of APS is huge and is well documented in some medical fields such as neurology (strokes, migraine, memory loss), cardiology (cardiac ischemia, syndrome X, valve lesions), gastroenterology (abdominal angina), dermatology (skin ulceration and necrosis, livedo reticularis and racemosa) and nephrology (renal thrombotic microangiopathy).
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APS and orthopedics?
The rheumatologic/orthopedic APS bond has been strengthening over the past few years and increasing attention has been paid to the locomotor aspect of the syndrome.
Known orthopedic manifestations of APS
Grossly, musculoskeletal complications of APS 2 may be classified into three categories:
1. pain/inflammation: arthralgia, complex regional pain syndrome type-1 (reflex sympathetic dystrophy), arthritis; 2. necrosis: avascular necrosis of bone, bone marrow necrosis, muscle infarction; 3. fragility: osteoporosis, non-traumatic fractures.
Joint pain and arthritis are quite common among APS patients À possibly due to secondary diseases such as Sjo¨gren's or lupus. Indeed, the prevalence of arthralgia and arthritis in major studies leans towards certain patient characteristics such as female gender and disease secondary to systemic lupus erythematosus (SLE). 3, 4 It is now clearer than ever that APS patients are at risk of avascular necrosis of bone (AVN); it may even be among the presenting symptoms 5 ( Figure 1 ). While the prevalence rates ranged widely between 0.9% 3 and 20%, 6 magnetic resonance imaging (MRI) clearly showed AVN in these patients. The latter study by Tektonidou et al. is of special interest, where the authors performed MRI on 79 patients. Twenty percent (20%) of the primary APS (PAPS) group (30 patients) had early and intermediate AVN, while none of the SLE (19 patients) and controls (30 subjects) showed signs of AVN on MRI. Interestingly, none of the study subjects had a history of corticosteroid intake, and AVN patients were younger, had a short disease duration, and developed livedo reticularis more often compared to non-AVN PAPS patients. 6 MRI remains the most sensitive study for identifying early AVN lesions, detecting more cases than X-rays and computed tomography (CT) scans.
More anecdotes reported bone marrow necrosis (BMN) in APS or in merely antiphospholipid antibody (aPL)-positive patients, with prevalence rates reaching up 13%. [6] [7] [8] [9] [10] [11] In this context, BMN is more commonly reported among catastrophic APS (CAPS) patients presenting with acute thrombotic episodes.
12-15 Special MRI sequences are now able to diagnose BMN non-invasively, and whenever possible, MRI should be the first diagnostic method of choice before performing a trephine bone marrow biopsy.
Less commonly, non-traumatic (stress) fractures were linked to APS secondary to SLE in one study 16 and to APS in case reports. [17] [18] [19] In 2004, Sangle and colleagues reported a series of APS patients with non-traumatic metatarsal fractures.
This observation opened the floodgates of reports of idiopathic fractures in APS, not only in the metatarsals but in a variety of bones. Sometimes the fractures are multiple, and recurrent. 18 The etiology of this tendency to bone fracture is not known, though bone ischemia seems a likely link.
Conflicting reports were published about the association of osteoporosis to APS, 20, 21 but the more common conclusion was that longstanding anticoagulation in APS patients is an indirect risk factor to develop osteoporosis, 21, 22 possibly related to the consequential vitamin D deficiency in anticoagulated APS patients. 21 Among many of the above-mentioned reports, the most striking piece of evidence suggesting a strong link between APS and its orthopedic complications is the symptomatic and radiologic improvement upon initiation of anticoagulation.
Future perspectives
. What is the real incidence and prevalence rates of these orthopedic manifestations among APS patients? . What is the exact role, if any, of aPL in the pathogenesis of these complications? How do spontaneous fractures occur in APS or in even aPL-positive patients? . Should MRI be ordered more frequently in APS patients complaining of leading orthopedic signs and symptoms? . Is anticoagulation the only treatment in such cases? . When should anticoagulation be initiated? . What is the target INR for primary and secondary prophylaxis in high-risk patients? . What is the role of the orthopedic surgeon in such cases?
. When to refer to rheumatology and when to attempt treatment of suspicious cases?
Each one of these questions, and perhaps many others, shall be answered by well-structured research protocols combining rheumatology and orthopedics. The involvement of the musculoskeletal system in the context of APS shall gain more widespread recognition between both parties in specific and in the medical society in general.
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